In one pilot study, Solexa re-sequenced a 140 kb genomic region on chromosome 1 in a HapMap sample. The data, presented at the recent Genomes, Medicine, and the Environment Conference, was meant to showcase the 1G’s ability to address different sequencing applications.
At the former GSAC conference last week, a Genome X Prize organizer invited researchers to "tell us what's wrong with [the guidelines and] where the flaws are” in order to "make sure nobody wins on a fluke."
The researcher, Mike Metzker, has been developing a reversible terminator chemistry for SBS sequencing. Eventually he wants his startup company, LaserGen, to wrap this chemistry and an imaging technology he developed into a sequencing instrument.
By next summer, ABI expects that the technology, called "Supported Oligonucleotide Ligation and Detection," or SOLiD, will generate up to 500 million bases of sequence data per run, but it has the potential to reach "North of 10 gigabases."
Making the enzyme better at incorporating modified nucleotides will likely be crucial for the success of next-gen technologies that employ nucleotide analogs, among them Solexa's and Helicos'. It could also lower the cost of standard Sanger sequencing.